clinical trials

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

Class action lawsuit filed against Corcept Therapeutics alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.

Generalized myasthenia gravis market valued at $5.9B in 2025, projected to grow 9.1% annually through 2036 as eight promising late-stage therapies advance.

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.

Galera and Obsidian merge in all-stock deal with $350M financing, creating Obsidian Therapeutics ($OBX) focused on TIL cell therapies with funding through 2028.

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.

Drug development services market projected to reach $50.26B by 2030 from $28.09B in 2025, driven by AI adoption, personalized medicine, and emerging market expansion.

CRISPR Therapeutics holds $2B cash reserves funding gene-therapy expansion, while Casgevy sales accelerate to $116M in 2025.

Alpha thalassemia market poised for significant expansion driven by rising prevalence, diagnostic advances, and pipeline therapies from $AGIOS and $NVO through 2036.

Schall Law Firm mobilizes class action against Aldeyra Therapeutics for alleged securities fraud tied to reproxalap drug claims. Eligible investors must participate by May 29, 2026.

Class action filed against $CORP alleging securities fraud over misleading statements about relacorilant clinical trials and FDA regulatory prospects.

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.

Artiva Biotherapeutics to present AlloNK cell therapy pipeline at Needham Healthcare Conference on April 15, 2026, advancing three ongoing autoimmune disease trials.